Mirum Pharmaceuticals, Inc.
MIRM
Rang in aandelen
#3220
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Aandeelprijs
$85.38
Marktkapitalisatie
$5.54B
Verandering (1 dag)
3.82%
Verandering (1 jaar)
16.91%
Land
US
Handel Mirum Pharmaceuticals, Inc. (MIRM)
Categorie
Healthcare
P/S-ratio voor Mirum Pharmaceuticals, Inc. (MIRM)
P/S-ratio op October 2026 TTM: 8.40
Volgens de meest recente financiële rapporten en aandelenkoers van Mirum Pharmaceuticals, Inc. is de huidige P/S-ratio (TTM) 8.40. Eind 2023 had het bedrijf een P/S-ratio van 6.48.
P/S-ratiohistoriek voor Mirum Pharmaceuticals, Inc. van 2018 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 8.40 | 44.09% |
| 2024 | 5.83 | -9.93% |
| 2023 | 6.48 | -24.37% |
| 2022 | 8.56 | -66.12% |
| 2021 | 25.27 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | 19.31% |
US
|
|
| 40.55 | 382.73% |
US
|
|
| 3.96 | -52.85% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 20.78% |
NL
|
